We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Active Biotech's Prostate Cancer Project TASQ in Therapy Trial
News

Active Biotech's Prostate Cancer Project TASQ in Therapy Trial

Active Biotech's Prostate Cancer Project TASQ in Therapy Trial
News

Active Biotech's Prostate Cancer Project TASQ in Therapy Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Active Biotech's Prostate Cancer Project TASQ in Therapy Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A Phase I Investigator sponsored clinical trial, led by Principal Investigator Dr.Andrew Armstrong at Duke University Hospital, US, has been announced for Active Biotech's prostate cancer project TASQ.

The primary objective for the CATCH trial (Cabazitaxel (Jevtana) And Tasquinimod in Men with Castration-Resistant Heavily pre-treated Prostate Cancer) is to determine the recommended dose of TASQ in combination with cabazitaxel based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC). Secondary objectives include efficacy as measured by progression free survival, and overall survival. The study will include about 30 CRPC patients. For further information about the study, please see www.clinicaltrials.gov.

In preclinical model systems of castrate-resistant prostate cancer, TASQ combined with taxane-based chemotherapy has been shown to further delay tumor progression.

A global, pivotal, randomized, double-blind, placebo-controlled Phase III study of TASQ in patients with metastatic CRPC is ongoing. The aim of the study is to confirm TASQ's effect on the disease, with radiological PFS as the primary endpoint and overall survival as secondary endpoint. The study will include about 1,200 patients in more than 250 clinics.

Advertisement